Treatment of Venous Thromboembolism in Real-Life Patients

Treatment of Venous Thromboembolism in Real-Life Patients: A Nationwide, Population-Based Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03087474

Enrollment

89383

Registered

2017-03-22

Start date

2015-12-04

Completion date

2018-06-28

Last updated

2018-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolism

Brief summary

In a population of patients with venous thromboembolism and treated with oral anticoagulants (OAC) in routine clinical practice in Denmark this study will describe patients treated with each OAC

Interventions

OTHERNon-Interventional

Non-Interventional

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. All patients ≥ 18 years diagnosed with incident VTE at Danish public hospitals from 2006 through 2015 2. First-time (index) VTE will be defined as an in- or out-patient diagnosis of DVT or PE among patients redeeming a prescription for anticoagulant drugs within 30 days after index date

Exclusion criteria

1\. In the analyses on type and duration of anticoagulant use, Patients with cancer will be excluded as they typically receive low molecular heparin directly from the hospital and their use of anticoagulants can therefore not be captured by redeemed prescriptions at pharmacies.

Design outcomes

Primary

Measure	Time frame	Description
Hospitalization rate in VKA patients for VTE	Approximately 180 months	Hospitalization rate for first-time Venous thromboembolism (VTE) in Vitamin K antagonist (VKA) patients
VTE hospitalization rate in VKA patients by sex	Approximately 180 months	—
VTE hospitalization rate in VKA patients by age	Approximately 180 months	—
Hospitalization rate in NOAC patients for VTE	Approximately 180 months	Hospitalization rate for first-time venous thromboembolism in nonvitamin K antagonist oral anticoagulants (NOAC) patients
VTE hospitalization rate in NOAC patients by sex	Approximately 180 months	—
VTE hospitalization rate in NOAC patients by age	Approximately 180 months	—
Duration of Treatment in NOAC patients	Approximately 180 months	—
Duration of treatment in VKA patients	Approximately 180 months	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026